Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 bridging study of topical roflumilast cream in mild to moderate atopic dermatitis
CTR20243893Phase 3Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of roflumilast in atopic dermatitis (AD), sponsored by Arcutis Biotherapeutics. Started Oct 2024; status: completed.
02
Drugs
roflumilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20243893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243893.